Zealand Pharma A/S

CPSE:ZEAL Stock Report

Market Cap: DKK 31.6b

Zealand Pharma Future Growth

Future criteria checks 0/6

Zealand Pharma's revenue and earnings are forecast to decline at 33.8% and 78.9% per annum respectively. EPS is expected to decline by 76.1% per annum. Return on equity is forecast to be -5.8% in 3 years.

Key information

-78.9%

Earnings growth rate

-76.09%

EPS growth rate

Biotechs earnings growth18.7%
Revenue growth rate-33.8%
Future return on equity-5.77%
Analyst coverage

Good

Last updated07 Sep 2025

Recent future growth updates

Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Aug 17
Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Recent updates

Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Aug 29
Zealand Pharma A/S' (CPH:ZEAL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks

Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.

Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Aug 17
Analysts Are Updating Their Zealand Pharma A/S (CPH:ZEAL) Estimates After Its First-Quarter Results

Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?

May 24
Is Zealand Pharma (CPH:ZEAL) Weighed On By Its Debt Load?

Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable

Mar 21
Most Shareholders Will Probably Find That The CEO Compensation For Zealand Pharma A/S (CPH:ZEAL) Is Reasonable

Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be

Feb 21
Zealand Pharma A/S (CPH:ZEAL) Analysts Are Way More Bearish Than They Used To Be

Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts

Dec 22
Analysts Just Made A Substantial Upgrade To Their Zealand Pharma A/S (CPH:ZEAL) Forecasts

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Nov 09
Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

Oct 01
Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

Earnings and Revenue Growth Forecasts

CPSE:ZEAL - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,927-466-1,422-1,72611
12/31/20264,4775101,7451,81615
12/31/20258,8265,7556,4727,10412
6/30/20259,1106,6817,5247,543N/A
3/31/202556-1,186-1,226-1,208N/A
12/31/202463-1,079-944-931N/A
9/30/202477-1,053-711-691N/A
6/30/2024368-712-538-508N/A
3/31/2024344-739-479-453N/A
12/31/2023343-704-449-426N/A
9/30/2023343-760-778-758N/A
6/30/202392-986-782-771N/A
3/31/2023107-1,064-831-822N/A
12/31/2022104-966-954-942N/A
9/30/202293-855-999-978N/A
6/30/2022104-845-1,083-1,060N/A
3/31/2022114-608-1,182-1,161N/A
12/31/2021109-755-1,234-1,212N/A
9/30/2021158-925-1,183-1,181N/A
6/30/2021161-1,012-1,085-1,071N/A
3/31/2021347-909-870-844N/A
12/31/2020192-669-714-689N/A
9/30/2020301-660-618-580N/A
6/30/2020255-545-670-632N/A
3/31/202054-624-698-671N/A
12/31/201941-572-433-409N/A
9/30/201943-508-408-391N/A
6/30/201933524927-346N/A
3/31/201928551N/A-320N/A
12/31/201838581N/A-461N/A
9/30/201835601N/A-417N/A
6/30/201874-361N/A-310N/A
3/31/201868-346N/A-320N/A
12/31/2017136-274N/A-279N/A
9/30/2017306-112N/A-64N/A
6/30/2017307-100N/A-113N/A
3/31/2017306-102N/A-52N/A
12/31/2016231-157N/A41N/A
9/30/2016221-138N/A-114N/A
6/30/2016189-158N/A-128N/A
3/31/2016188-139N/A-120N/A
12/31/2015188-114N/A-225N/A
9/30/201527-246N/A-216N/A
6/30/201578-178N/A-149N/A
3/31/201575-147N/A-146N/A
12/31/2014154-65N/A-42N/A
9/30/2014151-47N/A-50N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZEAL's earnings are forecast to decline over the next 3 years (-78.9% per year).

Earnings vs Market: ZEAL's earnings are forecast to decline over the next 3 years (-78.9% per year).

High Growth Earnings: ZEAL's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ZEAL's revenue is expected to decline over the next 3 years (-33.8% per year).

High Growth Revenue: ZEAL's revenue is forecast to decline over the next 3 years (-33.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ZEAL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/09 17:03
End of Day Share Price 2025/09/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yihan LiBarclays
Kerry HolfordBerenberg
Laura HindleyBerenberg